Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

ANI Pharma Inc (ANIP)

ANI Pharma Inc (ANIP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
ANI Pharmaceuticals to Participate at Leerink Partners Therapeutics Forum: I&I and Metabolism on July 8th

ANIP : 64.96 (-1.72%)
ANI Pharmaceuticals Announces Presentation of New Preclinical Data

ANIP : 64.96 (-1.72%)
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

ANIP : 64.96 (-1.72%)
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares

ANIP : 64.96 (-1.72%)
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ

ANIP : 64.96 (-1.72%)
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates

Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a loss...

IMCR : 35.02 (-1.21%)
PBYI : 3.39 (-3.69%)
ADMA : 18.51 (+0.22%)
ANIP : 64.96 (-1.72%)
ANI: Q1 Earnings Snapshot

ANI: Q1 Earnings Snapshot

ANIP : 64.96 (-1.72%)
ANI Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Raises 2025 Guidance

ANIP : 64.96 (-1.72%)
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y

Amarin Corporation AMRN reported a loss of 4 cents per share for the first quarter of 2025, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported...

BEAM : 21.16 (-3.95%)
AMRN : 16.93 (-2.25%)
ANIP : 64.96 (-1.72%)
NTLA : 11.53 (-5.14%)
ESPR's Q1 Earnings Miss Estimates, Revenues Beat, Stock Down

Esperion Therapeutics ESPR incurred a loss of 21 cents per share in the first quarter of 2025, which was wider than the Zacks Consensus Estimate of a loss of 18 cents. In the year-ago quarter, Esperion...

ESPR : 1.1900 (-4.03%)
IMCR : 35.02 (-1.21%)
ANIP : 64.96 (-1.72%)
NTLA : 11.53 (-5.14%)

Barchart Exclusives

Gold's Bull Run: Seasonal Strength Meets Conflicting COT Report—Are You In?
Gold's all-time high $3,509.9! Central banks bought big, but the COT report waves a red flag. Seasonal gains await—Market players, read or regret! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar